Colonoscopy vs. Blood Tests for Colorectal Cancer: What You Need to Know

Colonoscopy remains the gold standard for colorectal cancer (CRC) screening and prevention. Blood/stool tests are adjuncts, not replacements.

Why Colonoscopy Is Superior

• Direct visualization of entire colon/rectum.
• Therapeutic: Detects AND removes precancerous polyps (polypectomy) in same session.
• High sensitivity/specificity for neoplasia.
• Biopsy capability for definitive diagnosis.

Non-Invasive Tests (Adjuncts)

• FIT (fecal immunochemical test): Detects occult blood; annual; ~79% sensitivity for CRC, ~30% for advanced adenomas.
• gFOBT: Older guaiac test; lower sensitivity; dietary restrictions.
• mt-sDNA (Cologuard): DNA + blood; q3 years; ~92% CRC sensitivity, ~42% advanced adenoma.
• Blood-based (SEPT9, etc.): Emerging; not yet guideline-recommended for average-risk screening.

Guideline Recommendations (USPSTF, ACS)

• Average risk: Start at 45.
• Options: Colonoscopy q10y, FIT annually, mt-sDNA q3y, CT colonography q5y, flex sig q5y+FIT.
• Positive non-invasive test → diagnostic colonoscopy required.

Bottom Line

Only colonoscopy prevents CRC by removing precursors. Non-invasive tests detect existing cancer/large polyps. Choose based on preference, access, risk—but understand the trade-offs.